<DOC>
	<DOC>NCT00850252</DOC>
	<brief_summary>This study will assess the safety and efficacy of a completely autologous and completely biological tissue engineered blood vessel (TEBV) called Lifeline™ used as an arteriovenous fistula for dialysis access.</brief_summary>
	<brief_title>Use of a Lifeline Graft in the A-V Shunt Model</brief_title>
	<detailed_description />
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<criteria>Have signed an informed consent Patients ≥ 21 years old Patients not candidates for a BresciaCimino AV fistula (own vessels) Have an AV shunt or fistula that will likely fail within 12 months because of: Signs of clinical dysfunction: increment of venous pressure, limited site of puncture, stenosis, aneurysm dilatations that cannot be surgically repaired or by other media, or Previous angioplasty, or Previous thrombolysis Fall into category of ASA grade 2 or below (or UK equivalent) Are willing and able to comply with 2, 4, 6, 8, 10, 12, 16, 20, 24, 36 and 52 week follow up and able to comply with biannual follow up thereafter. A need for urgent surgery Penicillin allergy Patients with uncontrolled hypertension Morbid obesity (&gt; 300 lbs) Active systemic infection Contraindication for anticoagulation Coagulopathy Acute renal failure Connective tissue diseases (i.e. Marfan's syndrome) Pregnant or nursing Life expectancy &lt; 1 year Participation in another study involving an investigational device or new drug Other medical, social or psychological issues that, in the opinion of the principal investigator, preclude them from receiving the treatment and the procedures/evaluations of the postoperative follow up Inability or unwillingness to comply with the scheduled followup visit</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Lifeline</keyword>
	<keyword>Tissue engineered blood vessel</keyword>
	<keyword>A-V shunt</keyword>
</DOC>